We award a wide moat to Merck’s Life Science segment, resulting from intangible assets and switching cost moat sources. The Process Solutions division, which contributes 41% of the Life Science ...

Celonic Group, a Swiss-based CDMO, is integrating Merck’s Breez™ micro-bioreactor platform into its process development ... of innovative bioprocessing solutions,” Cimitan said.

Why it matters: Merck returned to growth in all three of its business segments during the fourth quarter, which saw a recovery from destocking in the life science segment. Healthcare remained the ...